Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Previous close
$53.35
−$2.96 · -5.26%
Regular session · ET · Market data may be delayed.
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Day range
Current $53.35
52-week range
Current $53.35
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
28
Expensive
Sentiment
70
Bullish
Risk
47
Elevated Risk
Momentum
53
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Day range
Current $53.35
52-week range
Current $53.35
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 145M USD | 104.2M USD | 60.59M USD | 35.29M USD | 25.76M USD |
| Selling, general, and administrative | 27.2M USD | 9.06M USD | 5.64M USD | 4.38M USD | 2.6M USD |
| Operating expenses | 172.19M USD | 113.27M USD | 66.23M USD | 39.39M USD | 28.36M USD |
| Interest income | 12.3M USD | 11.77M USD | 7.78M USD | 1.13M USD | 13.26K USD |
| Interest expense | 17.15M USD | 10.28M USD | 5.33M USD | 2.11M USD | 1.26M USD |
| Depreciation and amortization | 167K USD | 129.95K USD | 142.77K USD | 210.92K USD | 303.24K USD |
| Operating income | −172.19M USD | −113.27M USD | −66.23M USD | −39.39M USD | −28.36M USD |
| Net income | −177.04M USD | −111.78M USD | −63.78M USD | −40.37M USD | −29.61M USD |
Company facts updated Nov 22, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$160.67
201.16% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI76.52M0.00%689.3B USD0.03%$340.02-3.52%
State Street SPDR S&P Biotech ETFXBI69.09M0.72%9.64B USD0.35%$140.18-2.73%
iShares Russell 2000 ETFIWM56.6M0.08%71.54B USD0.19%$256.61-2.88%
Vanguard Extended Market ETFVXF32.34M0.03%30.2B USD0.05%$211.44-3.21%
iShares Russell 2000 Growth ETFIWO20.47M0.16%12.73B USD0.24%$320.43-3.57%
Vanguard Russell 2000 ETFVTWO15.64M0.09%16.8B USD0.06%$103.76-2.76%
Schwab U.S. Small-Cap ETFSCHA12.03M0.06%20.45B USD0.03%$30.51-2.83%
Vanguard Health Care ETFVHT5.43M0.02%20.8B USD0.09%$326.69-0.40%
Vanguard Morningstar Total Stock Market ETFVTI
State Street SPDR S&P Biotech ETFXBI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
Vanguard Russell 2000 ETFVTWO
Schwab U.S. Small-Cap ETFSCHA
Vanguard Health Care ETFVHTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.